Relevant Articles About Chronic Lymphocytic Leukemia (CLL)
Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
KEY TAKEAWAYS The study aimed to investigate the prevalence and outcomes of pathogenic BRCA1/2 variants in patients with early-stage BC. Researchers noticed that similar survival outcomes among gBRCAm and gBRCAwt patients indicate a need for broader screening...
KEY TAKEAWAYS The study aimed to investigate the role of m6A-modified lncRNAs in ferroptosis and cuproptosis during EC progression. Researchers noted that 5 hub lncRNAs could serve as potential biomarkers for targeted therapy and prognosis in EC. Endometrial cancer...
KEY TAKEAWAYS The study performed an exploratory biomarker analysis of immunophenotyping data from the ARTISTRY-1 clinical trial. The analysis suggests NK cell expansion as a potential predictive biomarker for nemvaleukin response in melanoma, requiring further...
Assessing the effectiveness of the standard frontline regimen comprising the BTKi ibrutinib in combination with or without the anti-CD20 antibody IO for older …
The phase 1 study assessed the safety and efficacy of rapcabtagene autoleucel in treating R/R DLBCL pts. The study’s primary endpoints were safety …
The study presented clinical safety data from the Phase I/II BRUIN trial focusing on pts who have been on pirtobrutinib for at least …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …
Background Novel early-line therapies for advanced (unresectable or metastatic) melanoma are needed to improve the rate of deep and durable responses and increase the proportion of patients with long-term benefit. TILVANCE-301 will evaluate the efficacy and …